Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferinject versus oral ferrous sulfate for iron deficiency anemia in inflammatory bowel disease
ISRCTN82615441Phase 3Completed
- Sponsor
- CSL Vifor
- Start
- Jun 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in iron deficiency anemia (IDA) and inflammatory bowel disease (IBD) comparing Ferinject intravenous infusion with Oral ferrous sulfate (2 arms). Primary endpoints: Change in hemoglobin at Week 12 and Safety and tolerability. Started Jun 2004; status: completed.
02
Drugs
ferric carboxymaltoseferrous sulfate
03
Conditions
iron deficiency anemia (IDA)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on ISRCTN82615441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN82615441.